JP2025512049A - 「good」緩衝液ベースのカチオン性脂質 - Google Patents

「good」緩衝液ベースのカチオン性脂質 Download PDF

Info

Publication number
JP2025512049A
JP2025512049A JP2024560403A JP2024560403A JP2025512049A JP 2025512049 A JP2025512049 A JP 2025512049A JP 2024560403 A JP2024560403 A JP 2024560403A JP 2024560403 A JP2024560403 A JP 2024560403A JP 2025512049 A JP2025512049 A JP 2025512049A
Authority
JP
Japan
Prior art keywords
bis
ethyl
mol
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512049A5 (https=
Inventor
フランク・デローザ
ホンフォン・デン
レベッカ・ゴールドマン
シュリーラン・カルヴィ
サスワタ・カルマカル
ラメシュ・ダサリ
ライアン・ランディス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ARP220100953A external-priority patent/AR125352A1/es
Priority claimed from TW111114318A external-priority patent/TW202309002A/zh
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2025512049A publication Critical patent/JP2025512049A/ja
Publication of JP2025512049A5 publication Critical patent/JP2025512049A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024560403A 2022-04-13 2023-04-13 「good」緩衝液ベースのカチオン性脂質 Pending JP2025512049A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
ARP20220100953 2022-04-13
ARP220100953A AR125352A1 (es) 2020-02-24 2022-04-13 Lípidos catiónicos a base de tampones de good
TW111114318 2022-04-14
TW111114318A TW202309002A (zh) 2021-04-15 2022-04-14 基於「古德」緩衝液的陽離子脂質
PCT/US2022/025067 WO2022221688A1 (en) 2021-04-15 2022-04-15 "good"buffer-based cationic lipids
USPCT/US2022/025067 2022-04-15
EP23305491.5 2023-04-04
EP23305491 2023-04-04
PCT/EP2023/059726 WO2023198857A1 (en) 2022-04-13 2023-04-13 "good" buffer-based cationic lipids

Publications (2)

Publication Number Publication Date
JP2025512049A true JP2025512049A (ja) 2025-04-16
JP2025512049A5 JP2025512049A5 (https=) 2026-04-21

Family

ID=86226317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560403A Pending JP2025512049A (ja) 2022-04-13 2023-04-13 「good」緩衝液ベースのカチオン性脂質

Country Status (5)

Country Link
US (1) US20250263385A1 (https=)
EP (1) EP4508039A1 (https=)
JP (1) JP2025512049A (https=)
CN (2) CN121318878A (https=)
WO (1) WO2023198857A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026008743A1 (en) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
AU2017357758B2 (en) 2016-11-10 2023-11-16 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
US20220233444A1 (en) * 2019-04-22 2022-07-28 Translate Bio, Inc. Thioester cationic lipids
WO2020227085A1 (en) * 2019-05-03 2020-11-12 Translate Bio, Inc. Di-thioester cationic lipids
WO2020257611A1 (en) * 2019-06-21 2020-12-24 Translate Bio, Inc. Cationic lipids comprising an hydroxy moiety
IL301536A (en) 2020-09-23 2023-05-01 Translate Bio Inc Cationic lipids based on piperazine
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
TW202309002A (zh) 2021-04-15 2023-03-01 美商轉譯生技公司 基於「古德」緩衝液的陽離子脂質

Also Published As

Publication number Publication date
EP4508039A1 (en) 2025-02-19
WO2023198857A1 (en) 2023-10-19
US20250263385A1 (en) 2025-08-21
CN121318878A (zh) 2026-01-13
CN121285547A (zh) 2026-01-06
WO2023198857A9 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
JP7791182B2 (ja) ピペラジンベースのカチオン性脂質
JP7791103B2 (ja) フェノール酸脂質系カチオン性脂質
JP7844452B2 (ja) Tesベースのカチオン性脂質
US20260021055A1 (en) Asymmetric Piperazine-Based Cationic Lipids
WO2025003759A9 (en) Dianhydrohexitol based ionizable lipids for nucleic acid delivery
JP2026500541A (ja) ビス-エステル及びアミドカチオン性脂質
US20250263385A1 (en) "Good" buffer-based cationic lipids
WO2025061967A1 (en) "good" buffer-based cationic lipids for nucleic acid delivery
EP4724456A1 (en) Sterol-based cationic lipids with aromatic head groups
WO2024256457A1 (en) Tricine and citric acid-based cationic lipids with aromatic head groups
AU2024306474A1 (en) Helper lipids for nucleic acid delivery
US20240270707A1 (en) "Good" buffer-based cationic lipids
US20230150921A1 (en) Phenolic acid lipid based cationic lipids
HK40099554B (en) Piperazine-based cationic lipids
HK40099554A (en) Piperazine-based cationic lipids
WO2026006524A2 (en) Bis-ester and amide cationic lipids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260410